Tag: Lymphoma
Brentuximab vedotin + Immunotherapy Shows 98% ORR and 93% CR in...
Updated efficacy and safety results from Part C of a phase 2 single-arm trial (SGN35-027; ClinicalTrials.gov identifier: NCT03646123; EudraCT 2020-004027-17) evaluating brentuximab vedotin (Adcetris®; Seagen/Takeda)* in combination with the PD-1 inhibitor nivolumab (Opdivo®; Bristol-Myers Squibb) and standard chemotherapy agents doxorubicin (Adriamycin®) and dacarbazine (DTIC-Dome®/Imidazole) for the frontline treatment of patients with early-stage classical Hodgkin lymphoma (cHL).
ASH 2019: Brentuximab Vedotin + Nivolumab in Frontline and R/R Hodgkin...
Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) and nivolumab (Opdivo®; Bristol‑Myers Squibb) in frontline Hodgkin lymphoma...
Health Canada Approves Brentuximab Vedotin + Chemotherapy in Frontline CD30-Expressing Peripheral...
Health Canada has approved the supplemental New Drug Submission that expands the use of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) in combination with CHP (cyclophosphamide,...
Pyrrolobenzodiazepine-based ADCs Demonstrate Potential in R/R Lymphomas
The International Conference on Malignant Lymphoma (ICML) has, since its first edition in 1981, become one of the must-attend conferences for the scientific community...
First Clinical Trial of STRO-001 Targeting CD74 to Treat Lymphoma and...
Researchers have begun dosing patients in its initial clinical trial of a new generation of precisely engineered - first-in-class - antibody-drug conjugate, or ADC,...
Long-term Data of Brentuximab Vedotin Redifines Treatment of Frontline Mature T-Cell...
Data highlighted at the 59th annual meeting of the American Society of Hematology (ASH) held in Atlanta, Georgia, December 9-12, 2017 shows final five-year...
TRPH-222, a Novel Anti-CD22 ADC, has Significant Anti-Tumor Activity in NHL
A preclinical abstract describing TRPH-222, also known as CAT-02-106, an anti-CD22 antibody-drug conjugate or ADC being developed by Triphase Accelerator for the treatment of...
Supplemental Biologics License Application for Brentuximab Vedotin in Frontline Advanced Hodgkin...
Based on positive results from the Phase III ECHELON-1 Clinical Trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with chemotherapy for the frontline...
Breakthrough Therapy Designation for Brentuximab Vedotin in CD30-expressing Mycosis Fungoides and...
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of patients with...
ISHL 2016: Seattle Genetics Commits to Improving Hodgkin Lymphoma Treatment
In a pre-conference announcement before the start of 10th International Symposium on Hodgkin Lymphoma (ISHL) taking place at the Gürzenich in Cologne, Germany, October 22-25,...
